Doç. Dr. Emir Çelik

• Lung Neoplasms 9 publications
  Source: OpenAlex / PubMed MeSHView publications
• Carcinoma, Non-Small-Cell Lung 7 publications
• Neoplasms 4 publications
• Breast Neoplasms 3 publications
• Colorectal Neoplasms 2 publications
• Rectal Neoplasms 2 publications
• Carcinoma, Renal Cell 2 publications
• Kidney Neoplasms 2 publications
• Colonic Neoplasms 2 publications
• Pancreatic Neoplasms 2 publications
• Disruptive, Impulse Control, and Conduct Disorders 2 publications
• Pituitary Neoplasms 2 publications
• Prolactinoma 2 publications

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: livhospital.com.

Experience

• ExperienceMuş Devlet Hastanesi 2021-2023 (Mecburi Hizmet)livhospital.com
• 2023Haydarpaşa Numune Eğitim ve Araştırma Hastanesilivhospital.com
• 2023-2025İstanbul Prof. Dr. Cemil Taşçıoğlu Şehir Hastanesilivhospital.com

Education

• 2007Alanya Fen Lisesilivhospital.com
• 2007-2013Cerrahpaşa Tıp Fakültesilivhospital.com
• 2014-2018Cerrahpaşa Tıp Fakültesi, İç Hastalıklarılivhospital.com
• 2018-2021Cerrahpaşa Tıp Fakültesi, Tıbbi Onkolojilivhospital.com

• SpecialtyMedical Oncologylivhospital.comFrom source
• InstitutionLiv Hospital Topkapılivhospital.comFrom source
• Area of workLung NeoplasmsExtracted from 9 publications · Model version —From source
• Publications64 publicationsOpenAlexFrom source
• Last synchronised4 November 2026 21:05https://www.livhospital.com/doc-dr-emir-celiklivhospital.com

1. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

   BMC Cancer, 2026

   DOI 10.1186/s12885-026-15725-9 PMID 41691201 Open-access full textSource: OpenAlex

2. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

   Therapeutic Advances in Medical Oncology, 2026

   DOI 10.1177/17588359261430583 PMID 41835339 1 citation (Europe PMC) Open-access full textSource: OpenAlex

3. Quality of Life and Healthcare Experiences of Patients with Anal Cancer: A Mixed-Methods Study

   Current Oncology, 2026

   DOI 10.3390/curroncol33050266 PMID 42187583 Open-access full textSource: OpenAlex

4. Prognostic factors and survival outcomes in older adults with extensive-stage small cell lung cancer: A multicenter retrospective cohort study

   Medicine, 2026

   DOI 10.1097/md.0000000000048711 PMID 42116366 Open-access full textSource: OpenAlex

5. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

   Clinical Cancer Research, 2026

   DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Source: OpenAlex

6. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

   Clinical Cancer Research, 2026

   DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Source: OpenAlex

7. Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

   Cancers, 2026

   DOI 10.3390/cancers18071170 PMID 41976392 Open-access full textSource: OpenAlex

8. The G8 tool for screening malnutrition before GLIM in geriatric cancer patients

   BMC Cancer, 2026

   DOI 10.1186/s12885-026-15977-5 PMID 41987111 Open-access full textSource: OpenAlex

9. The healthcare experience of solid rare cancer patients and their healthcare professionals: quantitative results from the eortc qol rare cancer study

   BMC Cancer, 2026

   DOI 10.1186/s12885-026-17156-y Open-access full textSource: OpenAlex

10. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14134568 PMID 40648939 3 citations (Europe PMC) Open-access full textSource: OpenAlex